Insmed (INSM) Q3 2025 earnings summary

Executive summary

• FDA approved BRINSUPRI (brensocatib) as the first treatment for non-cystic fibrosis bronchiectasis, launching in the U.S. in Q3 2025 and generating $28.1 million in net sales in its first six weeks, with broad physician adoption and strong patient interest.

• ARIKAYCE posted record quarterly revenue of $114.3 million in Q3 2025, up 22% year-over-year, with double-digit growth in all regions and international sales up 52%.

• Net product revenues rose 52% year-over-year to $142.3 million for Q3 2025, driven by BRINSUPRI's launch and ARIKAYCE's growth; total revenues for Q3 2025 were $142.3 million, up from $93.4 million in Q3 2024.

• Operating loss widened to $366.0 million for Q3 2025, reflecting higher R&D and SG&A expenses related to pipeline advancement and commercial activities.

• The company is advancing a robust late-stage and early-stage pipeline, with multiple phase II and III studies across respiratory and rare diseases, and expects several pivotal trial initiations and readouts in 2026.

Financial highlights

• Q3 2025 product revenues were $142.3 million, a 52% increase year-over-year, with ARIKAYCE contributing $114.3 million and BRINSUPRI $28.1 million.

• Cost of product revenues was $29.4 million (20.6% of revenues), reflecting improved gross margin due to BRINSUPRI's contribution.

• R&D expenses rose to $186.4 million and SG&A expenses to $186.4 million in Q3 2025, both up significantly year-over-year.

• Cash, cash equivalents, and marketable securities stood at approximately $1.7 billion at quarter-end, bolstered by a major equity offering.

• Net loss for Q3 2025 was $370.0 million ($1.75/share), compared to $220.5 million ($1.27/share) in Q3 2024.

Outlook and guidance

• 2025 global ARIKAYCE revenue guidance was raised to $420–$430 million, representing 15–18% year-over-year growth.

• BRINSUPRI's first full quarter (Q4 2025) will provide clearer insight into launch trajectory; analogs suggest high double-digit million revenue is a benchmark for strong respiratory launches.

• Multiple late-stage clinical milestones and pivotal trial initiations are expected in 2026, including topline data for brensocatib and ARIKAYCE, and phase 3 TPIP studies.

• Anticipated EMA decision on brensocatib by year-end, with potential EU launch in early 2026 and launches in the UK and Japan later in 2026.

• Cash and marketable securities expected to fund operations for at least the next 12 months.